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Abstract: Since its discovery in 1958, Burkitt lymphoma (BL) has been extensively studied 
and has become a model for tumorigenesis, but its pathogenesis has not been completely 
explained and understood yet. The aim of this review was to summarize the current knowledge 
about BL and, in particular, to discuss the role of miRNAs in its pathogenesis and their pos-
sible use as  diagnostic and prognostic indicators. The impact of viral-encoded miRNAs is also 
discussed, with the Epstein–Barr infection being almost invariably detected in the endemic 
variant of this tumor.
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Introduction
Discovery of Burkitt lymphoma (BL)
BL was first described by Denis Burkitt in 19581 during a field trip to sub-Saharan 
Africa and was subsequently named after him. The British surgeon observed that this 
particular tumor had a very high incidence in this geographic region, referred to as the 
“lymphoma belt” of Africa, in which other infectious diseases are also very common, 
such as malaria and arboviral infections.2,3 Nevertheless, even though ~60 years have 
passed since the first description, it is not clear yet what impact, if any, these infectious 
diseases may have in driving BL in endemic areas.4
BL has been referred to as the “Rosetta stone” of cancer because it is the first 
tumor for which a viral association has been described (with the Epstein–Barr virus 
[EBV]),5 the first tumor in which a specific chromosomal translocation has been iden-
tified (involving the MYC proto-oncogene)6,7 and the first tumor successfully treated 
by chemotherapy.8 For this reason, BL has a very important “historic” role, as it has 
improved our understanding of the molecular mechanisms happening in cancer, and 
it is still considered a model for tumorigenesis.
The EBV was isolated by Sir Anthony Epstein in 1964 from a BL-derived cell 
line,5 and now clear evidence highlight that this virus is not simply a bystander, but it 
actively promotes transformation through its encoded genome products.9
Classification of BL
According to the World Health Organization classification, BL can be defined as a “sin-
gle morphological and clinical entity, with variations in clinical presentation”.10 Three 
subtypes of this tumor have been described, namely, the endemic (eBL), the sporadic 
(sBL) and the immunodeficiency-associated form (ID-BL or human immunodeficiency 
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virus [HIV]-BL) that differ in geographic distribution and 
the extent of association with viruses, with EBV being the 
most relevant.10 Despite this distinction, these variants can 
still be considered the same entity as they all share the same 
clinical presentation and the same molecular profile,11,12 with 
some differences in their miRNA profile.13 The hallmark of 
BL is the constitutive activation of the MYC proto-oncogene, 
which leads to deregulated and increased expression of the 
Myc protein. In the vast majority of cases, this imbalance is 
achieved through a chromosomal translocation, which puts 
the MYC gene, mapping on chromosome 8, under the tran-
scriptional control of immunoglobulin (Ig) gene promoters. 
When these promoters are very active, following a transloca-
tion, there is a strong and sustained expression of the MYC 
gene, with a resulting upregulation of its protein product.6,7 
Three different translocations have been described involving 
different Ig loci (t[8;14], t[8;2] and t[8;22]), of which the 
t(8;14) is the most frequently observed in BL (~80% of BL 
cases).6,7 However, in the past 2 decades, it has been observed 
that BL cases overexpressing Myc, but lacking an identifiable 
translocation do exist.14 These cases are indistinguishable 
from translocated BLs with respect to clinical presenta-
tion and share the same gene expression profile,11 though 
they present with differences in their miRNA signature, as 
explained later in this review.15 This suggests that alternative 
pathogenetic mechanisms responsible for increased levels of 
the Myc protein exist, besides the chromosomal translocation. 
Interestingly, no differences regarding the presence of MYC 
translocation are observed among the different clinical vari-
ants of BL. BL immunophenotype shows the expression of 
B-cell-associated antigens (eg, CD19, CD20 and CD22) and 
additional proteins such as CD10, BCL6, CD38, CD77 and 
CD43, which suggests its derivation from late germinal center 
(GC) cells.10 However, it has been postulated that sBL and 
eBL derive from GC cells at different stages of differentia-
tion, as they show a different pattern of Ig hypermutation and 
signs of antigen selection.16 Based on this observation, it is 
possible that sBL derives from early GC cells (centroblasts), 
whereas eBL derives from late GC cells (centrocytes), as the 
latter show a higher number of somatic hypermutations in 
the Ig genes.16
Clinical variants of BL: endemic, sporadic 
and immunodeficiency associated
Despite BL showing a very homogeneous molecular pro-
file,11,12 differences can be pinpointed regarding the geo-
graphic distribution of this tumor and association with EBV. 
The endemic form has a very high incidence in Equatorial 
Africa, where other climatic conditions and infectious agents 
may possibly act as cofactors, though it is still debated at 
which extent and through which mechanisms.4 The endemic 
form of BL is preferentially observed in young children 
(especially males), with a peak incidence of 4–7 years. It 
most commonly presents in extranodal sites, with the jaw 
and other facial bones being very frequently affected. Most 
importantly, the degree of association of this clinical vari-
ant with EBV is extremely high, the virus being detected in 
~100% of eBL cases.10 Such a strong association suggests 
an active involvement of EBV in Burkitt pathogenesis, and 
recent literature proves an important role for its encoded 
products,9 although there is still a lot to uncover. Based 
on the simple association with EBV, 90–95% of the world 
population test positive for EBV, but BL incidence is much 
lower. This suggests that other factors may be required for 
BL pathogenesis.
The sporadic form occurs anywhere in the world and 
is histologically identical to eBL. It is still a pediatric dis-
ease, accounting for ~30% of childhood lymphomas (and 
1%–2% of all lymphomas), and yet has a higher incidence 
in males, though with a higher median age of incidence (12 
years). Another difference is that, despite sBL also showing 
an extranodal presentation, jaw tumors are less frequent, 
with the gastrointestinal tract being the most common site 
of involvement. Very interestingly, EBV is less commonly 
associated with sBL, being detected only in ~20%–30% 
of cases.10
As far as the immunodeficiency-related form is con-
cerned, this clinical variant is particularly frequent in 
HIV-positive individuals, accounting for one-third of HIV-
associated lymphomas, and it is therefore also referred to as 
HIV-related BL. This tumor is mostly observed in adults; it 
mainly shows a nodal presentation, with a generalized lymph 
node involvement and the bone marrow and central nervous 
system involvement also being common. Extranodal disease 
is possible, but it is much less frequent than in endemic 
and sporadic forms. The immunodeficiency-related variant 
shows a variable extent of association with EBV, ranging 
from 30% to 90% of all cases.10 Noteworthy, this form is 
not only observed in HIV-infected patients but also in other 
types of immunodeficiency (ie, posttransplant), although 
BL may be the first disease to manifest in HIV-infected 
individuals, as it occurs in patients with a still high CD4+ 
count and not having overt acquired immunodeficiency 
syndrome yet. This evidence suggests that, despite its role 
as an oncogenic virus still being debated, HIV may actively 
contribute to BL pathogenesis either indirectly, through a 
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continuous  antigenic stimulation, or directly, through its 
encoded genome products.17
MYC deregulation in BL
The MYC proto-oncogene is a powerful transcription factor 
and plays very important physiological functions, being 
involved in the control of proliferation, cell growth, metabo-
lism, apoptosis and differentiation.18 It belongs to the Myc 
family of transcription factors (comprising MYC, MYCN 
and MYCL), of which MYC is the best characterized. It was 
originally identified because of its homology with v-MYC, 
the transforming gene of the MC29 avian leukemia virus,19 
and subsequently, its deregulation has been reported in a 
wide range of human tumors, though its activation may 
be achieved through different pathogenetic mechanisms.20 
MYC may either induce or repress transcriptional activa-
tion, thus regulating the expression of many downstream 
targets and consequent biological pathways.21 To carry out 
transcriptional control, the Myc protein binds to other tran-
scriptional regulators such as Max or Mnt, Mxd1-4 (Mad1, 
Mxi1, Mad3 and Mad4) and Mga, which influence Myc 
transcriptional regulation pushing toward either activation 
or repression of downstream targets. Proliferative stimuli 
induce the expression of MYC and lead to the formation of 
Myc:Max heterodimers and concomitant activation of target 
gene expression, thus resulting in transcriptional activa-
tion.21 Other transcription factors may compete with Max 
for binding to Myc (Mnt, Mxd1-4 and Mga), thus resulting 
in transcriptional repression.22 In addition, Myc can bind 
to transcription factors Sp1 and Miz1 and may interfere 
with their transcriptional activator capability. The complex 
Myc–Miz1 recruits DNA methyl transferase 3a and histone 
deacetylase 3 to gene promoters, leading to DNA cytosine 
methylation and histone deacetylation, therefore causing gene 
expression silencing. The Myc–Miz1 complex can, therefore, 
induce the formation of heterochromatin on its target sites and 
function as a transcriptional repressor complex.22 Due to its 
key involvement in transcription regulation, Myc expression 
and function must be tightly controlled.
Pathological activation of MYC associated with gain-of-
function mutations has been commonly described in cancer. 
It can be due to chromosomal translocations leading to pro-
moter rearrangements (as observed in most BL cases), gene 
amplifications (commonly reported in breast cancer), virus-
mediated insertional mutagenesis (less commonly observed, 
due to random insertions of viruses within the genome) and 
Myc protein stabilization, mainly due to genetic mutations.21 
Though all these mechanisms are possible in BL, the most 
commonly observed cause of Myc deregulation is usually the 
presence of a balanced translocation involving chromosome 
8, where MYC maps, and different partners. Mutations of 
the MYC coding sequence have also been described in BL, 
as well as variations in its copy number, but they occur in a 
minority of cases23 and do not seem to account for the main 
reason of MYC upregulation. Nevertheless, in the last few 
years, a few cases of BL in which none of the abovementioned 
mechanisms could possibly explain Myc hyperexpression 
have been described, and alternative pathogenetic mecha-
nisms were investigated. No matter what is leading to MYC 
deregulation, the consequence is an increased expression 
of its protein product which is invariably associated with 
genomic instability, uncontrolled cell proliferation, escape 
from immune surveillance and malignant transformation.20
Additional genetic lesions in BL
Despite MYC deregulation being absolutely crucial for BL 
pathogenesis, MYC imbalance is not the only genetic lesion 
identified in BL and other recurrent or sporadic lesions have 
also been described. Several genes have been reported to 
be mutated in BL, such as the tumor suppressors ID324,25 or 
TCF3,26 whose mutations seem to be quite common in BL, 
especially in its sporadic variant. Additional mutations have 
been detected in genes belonging to the PI3K pathway,27 in the 
SWI/SNF family members and in ARID1A and SMARCA4A 
among others, which suggest functional alterations of the 
nucleosome remodeling complex.28 In addition, genes whose 
mutations have already been described in other B-cell lym-
phomas, such as MYC itself, DDX3X, CCND3 and FBXO11, 
among others, have also been reported to be mutated in BL.25,26 
Recently, mutations of particular genes have been reported to 
occur at a different frequency in eBL and sBL, and a correla-
tion between a distinct mutation pattern and the existence of 
some viral infections has been suggested.29 This observation 
may indicate that different pathogenetic mechanisms may 
exist in eBL and sBL and again suggests that viruses may 
play an active role in contributing to BL development.
Genetic lesions other than point mutations have also 
been described in BL. In particular, copy number altera-
tions including gains of 1q, 9q, 12q, 13q, 20q, 22q and Xq 
and losses of 4q, 13q and 17p have been reported.25,30–34 
Additionally, trisomy 1q31 and tetrasomy 1q have also been 
described.32 Interestingly, gains of 11q have been frequently 
reported in a subset of tumors resembling BL but lacking 
MYC translocation,35 although it is debated whether such 
cases should be diagnosed as BLs or rather as different 
aggressive B-cell tumors with a Burkitt-like presentation.35 
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In addition, uniparental disomy, whose role has been recently 
highlighted in cancer,36 does not seem to play a major role in 
the pathogenesis of BL.37
Myc upregulation due to impairment of 
post-transcriptional regulation: the role 
of miRNAs
Regulation of gene expression must be finely tuned and may 
be controlled at different levels. Transcriptional regulation 
can be achieved by epigenetic changes, which regulate the 
accessibility of specific DNA sequences through methylation 
of histones and DNA, thus determining a conformational 
change in the chromatin and preventing the expression of 
genes when their function is not required. Regulation of gene 
expression is further controlled at the post-transcriptional 
level, when a certain mRNA has already been transcribed, 
but translation into the correspondent protein product is 
impaired. Post-transcriptional regulation is achieved by small 
non-coding RNAs, of which miRNAs have been intensively 
studied in the last few years.
miRNAs were isolated for the first time from Caenorhab-
ditis elegans in 1998,38 and since the first observation, they 
have been described in a wide range of organisms, includ-
ing humans. They are small sequences of non-coding RNA 
that, in their mature form, have sizes of 18–24 bp, though 
they are processed from longer precursors during a matura-
tion process that also shuttles them from the nucleus to the 
cytoplasm.38 After maturation, the miRNAs bind to comple-
mentary mRNA sequences and prevent their translation into 
the corresponding proteins. Depending on their degree of 
complementarity with the target mRNAs, they can either 
lead to mRNA degradation, when there is a perfect pairing, 
or simply to translation impairment, if there are mismatches 
in the pairing. However, no matter whether the mRNA is 
degraded or not, the consequence of miRNA–mRNA bind-
ing is that production of the protein coded by that particular 
mRNA is prevented. This further level of regulation allows 
shutting down the expression of specific genes even when 
their transcription into an mRNA has already taken place. 
More importantly, it is worth mentioning that a single miRNA 
can target hundreds of mRNAs based on a short sequence 
complementarity. Deregulation of a single miRNA may, 
therefore, result in deregulated expression of many genes, 
thus affecting several distinct pathways and biological func-
tions within the cell. With the function of miRNA being so 
delicate in tuning the gene expression, their function must be 
strictly controlled as its imbalance might lead to disturbance 
of gene expression. Deregulation of miRNA expression and 
function has, therefore, been reported in a plethora of human 
diseases, including cancer.39
MYC and miRNAs control each other’s 
expression: the existence of a feedback 
regulatory loop
We have already mentioned the importance of MYC as a 
transcription regulator. With its capability to bind to target 
sequences on DNA, Myc can control the expression of coding 
as well as non-coding regions in the DNA, including genes 
and miRNAs. Myc is known to regulate the expression of 
~60 miRNAs,40,41 either positively or negatively influencing 
their expression (Figure 1). As a transcriptional activator, 
Myc can induce the expression of selected miRNAs, of 
which the miR-17-92 cluster is the prototypical example,42 
thus influencing the expression of miRNA downstream tar-
get genes and eventually influencing the related biological 
processes (Figure 2A). Induction of miR-17-92 by MYC has 
been previously reported not only in BL and other B-cell 
tumors42 but also in various different tumors including 
breast, lung, colon, stomach and prostate (for a review, see 
Bui and Mendell43). Inhibition of downstream target genes 
of the miR-17-92 cluster enhances tumorigenicity by boost-
ing cell proliferation, tumor cell survival and angiogenesis, 
along with metabolic reprogramming.43 Very interestingly, 
among the downstream targets of this cluster, there are tumor 
suppressors such as PTEN and BIM, the first gene being an 
antagonist of PI3K activity and the latter having a proapop-
totic function.43–46 Overexpression of miR-17-92 induced 
by Myc, therefore, results in loss of regulatory control on 
cell growth mediated by these tumor suppressors. A recent 
study investigated the expression of each member of this 
cluster in BL and analyzed whether there was a correlation 
between their expression and prognosis of BL.47 The results 
of this study indicated that miR-17 and miR-20a were highly 
expressed in BL and  determined lack of expression of the 
Bim protein.47 In addition, a significant correlation between 
high levels of miR-17 and poor overall survival was also 
recorded, thus indicating the influence of miRNA expression 
as a prognostic value in BL.47
At the same time, Myc can also repress the expression 
of specific miRNAs (ie, the miR-29 family), thus leading to 
increased expression of miRNA target genes and imbalance 
of cellular pathways (Figure 2A). However, MYC itself is a 
gene and, therefore, its expression is also controlled at the 
post-transcriptional level by miRNAs, of which probably the 
best studied is the let-7 family.48 MYC expression, both at the 
transcriptional and post-transcriptional levels, is therefore 
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controlled through different mechanisms to ensure that this 
protein will be produced only when its function in the cell 
is needed. Thus, miRNAs–MYC form a feedback regulatory 
loop controlling each other’s expression in an inverse and 
reciprocal manner (Figure 1). When this miRNAs–MYC 
autoregulation fails, the expression of MYC and miRNAs is 
no longer regulated and may result in diseases and cancer.
A recent study reported the upregulation of the YY1 gene, 
which is an oncogenic transcription factor able to induce MYC 
expression, in BL as a consequence of downregulation of 
specific miRNAs.49 This transcription factor was previously 
found to be upregulated in other non-Hodgkin’s lymphomas 
(NHLs)50,51 and plays a role in resistance to chemotherapy 
and immunotherapy in NHL cell lines.52 YY1 can also act 
as a transcriptional repressor of tumor suppressors such as 
p16, p27, p73 and p53.53–55 In particular, its inhibitory effect 
on p53 is related to evasion from apoptosis,56 which may be 
crucial for transformed cells, pointing at YY1 as an indicator 
of aggressiveness in NHLs. Very interestingly, upregulation 
of YY1 reported in this study is a consequence of repression 
of specific miRNAs, some of which, such as has-miR-363 and 
hsa-miR-200a, are among the top 20 miRNAs repressed in BL, 
thus reinforcing its functional role in the pathogenesis of BL.49
Exploring the MYC–miRNA interaction in 
BL: sustaining Myc hyperexpression in the 
absence of a translocation
Approximately 10% of BL cases lack an identifiable MYC 
translocation, but do express the Myc protein at a level com-
parable to MYC-translocated BL cases.57 This observation 
prompted many scientists worldwide to explore alternative 
pathogenetic mechanisms that could explain a higher expres-
sion of Myc in the absence of genetic lesions, either trans-
location or copy number alterations. Given the functional 
relationship between MYC and miRNAs, one possible scenario 
to explore was to investigate whether there was an imbalance 
in MYC-regulating miRNA expression that could eventu-
ally explain increased Myc protein levels. A pioneer study 
published in 2008 compared the expression of six miRNAs 
predicted to target MYC (hsa-miR-155, has-miR-30a-3p, hsa-
miR-34b, hsa-let-7c, hsa-let-7a and hsa-miR-98) between BL 
cases carrying or not an MYC translocation.57 The results of 
Figure 1 An overview of MYC–miRNA regulatory loop and related pathways. 
Note: miRNAs upregulated by Myc are indicated by the red arrow and the downregulated miRNAs are indicated by the blue arrow.
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this study highlighted a diminished expression of two of them 
(hsa-let-7a and hsa-miR-34b), thus suggesting that increased 
expression of Myc may be a consequence of downregulation 
of specific miRNAs.57 However, of even greater interest was 
the observation that hsa-miR-34b was downregulated only in 
BL cases lacking the translocation, whereas reduced expres-
sion of hsa-let-7a was observed in all BL cases, irrespective 
of the translocation status. This observation suggested the 
alteration of hsa-miR-34b as potentially responsible for Myc 
hyperexpression in the absence of any genetic lesions.57 A later 
study of the same group identified hsa-miR-9* as a second 
miRNA specifically downregulated only in BL cases lacking 
MYC translocation.58 This observation was of particular inter-
est because hsa-miR-9* does not directly target MYC, but may 
indirectly regulate its expression through E2F1, whose expres-
sion is induced by Myc,59,60 and that in turn activates MYC 
expression through a feedback autoregulatory loop that also 
involves the miR-17-92 cluster.61–63 Hsa-miR-9* downregula-
tion observed in BL cases lacking MYC translocation could 
determine the upregulation of E2F1, which then increases and 
sustains MYC expression. The complete miRNA expression 
profile was then investigated in BL cases with or without MYC 
translocation and differential expression of four miRNAs 
(hsa-miR-29a, hsa-miR-29b, hsa-miR-513a-5p and hsa-miR-
628-3p) was identified.15 A single miRNA is able to control the 
expression of many target genes. Therefore, we investigated 
the impact of the 4 dysregulated miRNAs so-identified on the 
global gene expression and identified 64 putative target genes 
Figure 2 An overview of the pathways affected by Myc-regulated miRNAs.
Notes: (A) Myc-induced miRNAs and their regulated pathways. EBV-encoded miRNAs may compete with the miR-17-92 cluster for regulation of the same target genes. (B) 
Myc-repressed miRNAs and their regulated pathways. EBV-encoded BARTs may compete with cellular miR-29 family members.
Abbreviation: EBV, Epstein–Barr virus.
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of such miRNAs were identified by bioinformatics.15 The 64 
predicted target genes are involved in important biological 
processes such as gene expression regulation, proliferation 
and DNA modification. Very interestingly, among differen-
tially expressed genes, some, such as MYCN and the DNMT 
family of proteins, were of particular interest, with MYCN 
being a homologue of MYC and the DNMT proteins being 
reported to be altered in cancer very frequently.64 DNMTs were 
reported to be specifically upregulated in BL cases lacking the 
translocation, suggesting that an aberrant epigenetic control 
occurs in this set of BL cases. As discussed earlier, interaction 
of Myc with DNMT family members can influence chromatin 
conformation and subsequent accessibility to RNA polymerase 
for transcription.22 Deregulation of DNMTs by the miR-29 
family has also been recently described in another study, which 
highlights the importance of epigenetic regulation in BL.65 In 
particular, this study shows hypermethylation of p16 following 
overexpression of DNMTs, which might favor cell prolifera-
tion due to lack of control on cell cycle.65 Of great interest is the 
finding that MYCN overexpression occurs only in cases lacking 
MYC translocation. MYCN expression is usually not detected 
in BL cases, but its deregulation is frequently observed in 
other cancers, such as neuroblastoma, where there is a different 
genetic mechanism (amplification of the MYC gene) which 
is responsible for over-expression of the Myc protein.66 High 
expression of MYCN in cases lacking MYC translocation may 
indicate the existence of an alternative cooperative mechanism 
ensuring high expression of members of the MYC family in the 
absence of genetic lesions involving MYC. Very interestingly, 
deregulation of two of the differentially expressed miRNAs 
(miR-513a-5p and miR-628-3p) has been recently described 
in human neuroblastoma,67,68 with the miR-628-3p expression 
correlating with the prognosis of this tumor.69
MYC pathway in BL: downregulated 
miRNAs target genes belonging to the 
MYC pathway
Several genes are transcriptionally controlled by Myc, and the 
existence of an MYC pathway has been identified in cells. As 
Myc is highly expressed in BL, it was investigated to what 
extent the Myc-regulated pathway was affected in BL and 
through which mechanisms. Results from a previous research 
study report that MYC target genes are upregulated in BL or 
gamma-irradiated mice tumors.70 In this study, 41 miRNAs 
were found to be downregulated in gamma-irradiated mice 
lymphomas and 17 miRNAs in BL, resulting in upregulation 
of miRNA target genes. Interestingly, an enrichment of the 
MYC pathway was observed among upregulated genes, thus 
suggesting that upregulation of MYC pathway may be a con-
sequence of transcriptional repression of specific miRNAs.70
miRNA expression profile: a BL signature 
for differential diagnosis
BL is a very homogeneous entity in terms of gene expression 
and has a distinctive, unique pattern, which distinguishes it 
from any other B-cell lymphomas.11,12 This observation is 
extremely useful for diagnostic purposes, as we can classify 
borderline cases or cases with a histologic “Burkitt-like” 
presentation based on their distinctive molecular profile.11,12 
Despite showing some subtle differences in their miRNA 
profile, only a few differences can be identified at the gene 
expression level in cases with or without MYC translocation 
after enrichment, yet indicating a very high homogeneity of 
these tumors. The three clinical forms of BL share the same 
molecular signature, although differences in gene expression 
can be observed between EBV+ and EBV− BL cases.71 How-
ever, such variations may be attributed to the presence of the 
virus rather than to differences between clinical variants.71 
The miRNA profile of BL was analyzed and compared to that 
of diffuse large B-cell lymphoma (DLBCL); a signature of 38 
miRNAs was identified, which comprises MYC-regulated and 
nuclear factor-kB-associated miRNAs.13 The same study also 
reported that only six miRNAs were differentially expressed 
between eBL and sBL, thus reinforcing the notion that BL is a 
very homogeneous entity and its molecular uniqueness can be 
used for differential diagnosis with other B-cell lymphomas.13
More recently, additional studies have confirmed the 
efficacy of miRNA profile for differential diagnosis and have 
proved that its reliability can be comparable to gene expres-
sion profile results, so far considered the “gold standard” for 
molecular analyses. A recent study identified a 27-miRNA sig-
nature able to distinguish BL from DLBCL, which could also 
be validated in formalin-fixed paraffin-embedded cases, thus 
even reinforcing its possible diagnostic application.72 Another 
research identified by deep sequencing the existence of a 
22-miRNA signature, which could be used to discriminate BL 
from DLBCL and follicular lymphomas, again highlighting the 
importance of molecular profiles for differential diagnosis.73
Noteworthy, low or no expression of hsa-miR-155 (or its 
precursor BIC) was detected in BL, as reported by several 
studies,74–76 despite this miRNA being one of the most com-
monly upregulated in B-cell lymphomas.77–79 It has been 
recently demonstrated that low levels of this miRNA deter-
mine an increased expression of AICDA, which increases 
the frequency of MYC translocation.80 Intriguingly, a study 
shows that higher expression of miR-155 can be found in a 
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subset of EBV-positive BL cell lines expressing a viral latency 
III program, which is usually not detected in primary BLs, 
whereas low or no expression of this miRNA was detected 
in EBV-positive BL cases expressing a latency I program, 
which represent the vast majority of BLs.75 It has sometimes 
been speculated that EBV infection may promote MYC 
translocation in BL. This observation may suggest a possible 
mechanism leading to MYC translocation in EBV-positive 
cases by maintaining low miR-155 and consequently induc-
ing AICDA expression. Interestingly, downregulation of this 
miRNA can also be used for differential diagnosis,81 as high 
expression of miR-155 is normally reported in other B-cell 
tumors, where it seems to have a clinical significance as it is 
associated with chemotherapy failure in DLBCL.72
Tables 1 and 2 list the miRNAs whose expression has 
been reported to be unbalanced in BL.
Virus-encoded miRNAs and deregulation 
of host cell gene expression: contribution 
of EBV
EBV is very often associated with BL, especially in its 
endemic form. Despite an extensive discussion about this 
virus, with its latency programs and pathogenetic mecha-
nisms being beyond the aim of this review, it is worth men-
tioning that EBV may contribute to the pathogenesis of BL 
through its encoded proteins (genes and viral miRNAs). 
In BL cells, EBV expresses a latency I program, in which 
EBNA1 is the only viral protein expressed. Previous studies 
have demonstrated the role of this protein in the pathogenesis 
of BL.82,83 EBV also encodes for 44 mature viral miRNAs 
(viRNAs) belonging to two families (BART and BHRF).84 
Expression of these viral-encoded miRNAs is also latency 
regulated, and only a few viRNAs belonging to the BART 
family are detected in BL.85 It has also been demonstrated 
that three members of the BART family (BART-1-3p, BART-
5-5p and BART-22-3p) exhibit high similarity with cellular 
miRNAs, including the miR-29 family (Figure 2B).86–91 
The expression of viRNAs should be carefully monitored 
as they compete with cellular miRNAs for the same target 
genes in the host cell. An interesting study has shown that 
in a BL-derived cell line expressing a latency III program, 
EBV-encoded miRNAs target the same genes as the miR-
17-92 cluster (Figure 2A).92 Despite the BL primary tumors 
mostly expressing a latency I program, this observation is of 
Table 1 List of miRNAs reported to be downregulated in BL
Downregulated miRNAs References
hsa-miR-221, hsa-miR-155, hsa-miR-146a, hsa-miR-146b-5p, hsa-miR-26b, hsa-miR-23a, hsa-miR-30d, hsa-miR-107, hsa-
miR-103, hsa-miR-222, hsa-miR-26a, hsa-miR-30a, hsa-miR-142-5p, hsa-miR-23b, hsa-miR-342-3p, hsa-miR-29b, hsa-miR-34b
13
hsa-let-7a, hsa-miR-34b 57
hsa-miR-9* 58
hsa-miR-29a, hsa-miR-29b 15
hsa-155, hsa-196b, hsa-885-5p, hsa-222, hsa-135b, hsa-21, hsa-31, hsa-708, hsa-23a, hsa-455-5p, hsa-455-3p, hsa-29b, hsa-29c, 
hsa-342-5p, hsa-146a, hsa-150
72
hsa-513, hsa-18b, hsa-15b, hsa-454-3p, hsa-148a, let-7f, hsa-98, hsa-363, hsa-582, hsa-146, hsa-155, let-7d, hsa-26b, hsa-29b, 
hsa-142-3p, hsa-16, hsa-15a, hsa-590, hsa-32, hsa-331, hsa-138, hsa-28
70
hsa-miR-664-3p, hsa-miR-664-5p, hsa-miR-150-3p, hsa-miR-150-5p, hsa-miR-155-5p, hsa-miR-184, hsa-miR-196b-5p, hsa-miR-
151b, hsa-miR-211-5p, hsa-miR-221-3p, hsa-miR-29c-5p
73
hsa-miR-155 74–76
Abbreviation: BL, Burkitt lymphoma.
Table 2 List of miRNAs reported to be upregulated in BL
Upregulated miRNAs References
hsa-miR-371-5p, hsa-miR-185, hsa-miR-93*, hsa-miR-326, hsa-miR-497, hsa-miR-26b*, hsa-miR-339-5p, hsa-miR-485-3p, 
hsa-miR-9, hsa-miR-193a-5p, hsa-miR-448, hsa-miR-202*, hsa-miR-483-3p, hsa-miR-26a-1*, hsa-miR-328, hsa-miR-192, hsa-
miR-429, hsa-miR-324-5p, hsa-miR-340, hsa-miR-105*, hsa-miR-124*
13
hsa-miR-17-92 42
hsa-miR-513a-5p, hsa-miR-628-3p 15
hsa-296-5p, hsa-296-3p, hsa-130b, hsa-18a, hsa-18b, hsa-19a, hsa-19b, hsa-20a, hsa-20b, hsa-17, hsa-106 72
hsa-202, hsa-92, hsa-19a, hsa-19b, hsa-296, hsa-663, hsa-22, hsa-320, hsa-181b, hsa-422b, hsa-484 70
hsa-miR-17-3p, hsa-miR-18a-3p, hsa-miR-19a-3p, hsa-miR-20a-3p, hsa-miR-25-5p, hsa-miR-93-3p, hsa-miR-106b-3p, hsa-miR-
106b-5p, hsa-miR-130b-3p, hsa-miR-296-3p, hsa-miR-335-3p, hsa-miR-339-5p, hsa-miR-573, hsa-miR-4521
73
hsa-miR-21, hsa-miR-23a 100
Abbreviation: BL, Burkitt lymphoma.
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interest as it highlights how EBV infection may contribute 
to deregulate key cellular pathways such as transcription, 
apoptosis and cell cycle.92 Expression of viRNAs could, 
therefore, result in an aberrant post-transcriptional regula-
tion in infected cells. The presence of EBV can impact on 
cellular miRNA signature in BL85,93 and on cellular gene 
expression profile.93 An important role for EBV-Bart6 has 
been suggested, as this miRNA is capable of regulating the 
expression of PTEN and interleukin-6 receptor complex in 
infected cells, thus influencing survival and interleukin-6 
downstream pathways.85 A later study confirmed this finding 
and highlighted the existence of a synergistic effect between 
Bart-6 and miR-142, which was previously reported to be 
upregulated in BL,85 to repress PTEN.94 This latter observa-
tion is of interest as it highlights the active role of EBV in BL 
pathogenesis and its interplay with the cellular machinery. 
It has also been demonstrated that BARTs target Casp3 in 
BL and may therefore result in an antiapoptotic effect, thus 
resulting in a growth advantage for the infected cells.95
It is worth mentioning that EBV infection contributes 
to lymphomagenesis also through mechanisms other than 
miRNA regulation. We had previously mentioned that a dif-
ferent mutational profile can be observed between eBL and 
sBL, with endemic cases showing a lower mutation rate.29 
With the degree of association with EBV being the main 
difference between the endemic and sporadic variants, it is 
reasonable to postulate that such difference may be due to 
the existence of additional pathogenetic mechanisms in EBV-
positive cases.29 In a recent research paper, the methylome 
of EBV-positive vs EBV-negative BL-derived cell lines was 
compared, and the results of this study demonstrated that 
the presence of the virus is associated with a specific pattern 
of DNA methylation, suggesting that EBV may contribute 
to BL pathogenesis through an epigenetic mechanism.96 
In particular, this paper has demonstrated a higher level 
of methylation in EBV-positive samples involving, among 
others, key genes such as ID3 and TCF3 which are usually 
mutated in sBL, but whose mutation rate is lower in eBL.29 
Diminished expression of these genes in eBL may, therefore, 
be a consequence of epigenetic regulation rather than deriv-
ing from genetic lesions. This finding suggests that BLs have 
similar gene expression patterns, but underlying mechanisms 
may be different and may depend on the presence of EBV.96
Although an extensive discussion of other parasites 
that might act as cofactors in Burkitt lymphomagenesis is 
beyond the scope of this review, it is worth making a brief 
comment on another parasite, the protozoon Plasmodium 
falciparum that causes malaria, as there is a striking overlap 
in the  geographic incidence of eBL and this disease. Even 
though not much is known about the mechanisms that 
the parasite uses to contribute to tumor formation, recent 
literature shows that P. falciparum infection drives EBV-
infected cells through GC, and it is capable of deregulating 
the expression of the AICDA gene (also referred to as AID), 
which would lead to chromosomal translocations, as we 
mentioned earlier.97–99 Translocations would mainly occur 
in EBV-infected cells within the GC that more likely would 
tolerate it. This observation reinforces the speculation that 
other cofactors are required for the occurrence of BL in 
endemic areas and that these parasites play an active role in 
Burkitt lymphomagenesis.
miRNAs as prognostic indicators of BL
Given the clear involvement of miRNA deregulation in the 
pathogenesis of BL, their diagnostic and prognostic value has 
been evaluated. A recent study reports that the identification 
of three circulating miRNAs (miRNA-21, miRNA-23a and 
miRNA-125b) in the plasma of BL patients may be used as 
a diagnostic indicator and could be related to clinicopatho-
logic parameters.100 Increased expression was observed for 
miR-21 and miR-23, and it was also correlated with some 
clinicopathologic parameters (tumor staging, increased 
white blood cells, increased serum lactate dehydrogenase 
level, CD10 expression and size of the tumor >6 cm).100 
Very interestingly, the expression level of these miRNAs 
decreased significantly following chemotherapy, suggesting 
that these miRNAs could be used to monitor therapy effi-
cacy.100 Also, an inverse correlation between the level of these 
miRNAs and patients’ outcome was established, indicating 
these miRNAs act as prognostic indicators as well.100 Very 
recently, the expression of another miRNA (hsa-miR-10a-5p) 
has been linked to the prognosis of BL patients, with this 
being downregulated in non-survivors.101 Interestingly, genes 
targeted by this miRNA are involved in control of apoptosis 
and their overexpression could favor cell growth. Addition-
ally, high expression of CD59 as a result of hsa-miR-10a-5p 
imbalance may determine reduced sensitivity to chemo- and 
immunotherapy and explain treatment failure and reduced 
overall survival in BL.101
miRNAs as potential targets in novel 
treatments for BL
BL is classically treated by a combination of chemotherapy 
and immunotherapy.102 Nevertheless, due to the aggressive-
ness of this tumor, it is imperative to explore more effective 
therapeutic alternatives. One such possibility would be to 
Blood and Lymphatic Cancer: Targets and Therapy 2018:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
42
Videtta et al
target miRNAs to either suppress or induce the expression of 
target genes, which might be relevant for a better prognostic 
outcome. Recent literature is providing useful information 
about new drugs or possible new therapeutic targets, includ-
ing miRNAs. An obvious target for BL treatment would be 
MYC and its related network. A recent study reports that 
the use of INZ(c), a second generation of Inauhzin, is able 
to suppress Myc expression and it results in inhibition of 
cell growth in lymphoma cells.103 Suppression of MYC is 
achieved through the miRNA pathway, as the expression of 
MYC-targeting miRNAs, such as miR-24 and miR-34a, is 
induced upon treatment to reduce Myc levels.103 Noteworthy, 
this small molecule does not have considerable side effects 
and could be used in combination with doxorubicin to reduce 
Myc expression, allowing the administration of a lower dose 
of doxorubicin with consequent reduction of side effects.103 
However, due to the pleiotropic activities regulated by MYC, 
it is very difficult to design therapeutic approaches to inhibit 
its expression in human tumors without interfering with its 
physiological functions, and other potential targets should 
be explored.
Treatment with the combination of histone deacetylase 
inhibitor and chemotherapy results in induction of apoptosis 
in BL cells through the proapoptotic BCL2-related family 
member Bim protein.104 A recent study of the same group 
describes that the use of combination of histone deacetylase 
inhibitor and chemotherapy could prevent cell growth in 
BL by regulating PI3K/Akt, suggesting that other targets, 
such as the PI3K/Akt signaling network, in addition to MYC 
should be further explored.105 The combination of demethyl-
ating agents and chemotherapy could be used to revert the 
expression of aberrantly silenced genes and miRNAs, such 
as p16 and miR-101, miR-143 and miR-145, in BL tumor 
models.105 Of these, miR-145 directly targets MYC and is 
expressed through the PI3K pathway, which is deregulated 
in BL.106 Re-expression of miR-145 by this combinatorial 
approach may, therefore, result in reduction of MYC expres-
sion levels.105
Regulation of cell proliferation and induction of a more 
differentiated phenotype could be another possible approach 
as BL is the fastest growing tumor. It has been recently 
reported that the re-expression of miR-150 could be used as 
a possible promising therapeutic target because of its capabil-
ity of reducing cell proliferation by targeting B-Myb.107,108 
In addition, this would result in the acquisition of a more 
differentiated phenotype as BL results from an impairment 
during differentiation toward plasma cells.109,110
Conclusion
MYC overexpression is the hallmark of BL and it can be 
consequent to several pathogenetic mechanisms. Recent lit-
erature highlights the key role of miRNAs in the pathogenesis 
of BL that can imbalance Myc and its associated pathways. 
Detection of miRNA expression can be used for diagnostic 
and therapeutic purposes. Re-expression of endogenous 
miRNAs through the administration of demethylating drugs 
to revert their silencing, or ectopic introduction of exogenous 
small RNAs that target deregulated genes could represent an 
exciting alternative to current therapies to improve the overall 
survival and reduce the side effects in BL patients. However, 
despite encouraging results, there is still much to uncover 
before such innovative therapeutic approaches may enter 
daily practice, and research in the field should be pursued to 
better clarify their role in the pathogenesis of BL.
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